Literature DB >> 22143180

Osteoporosis in 2011: Osteoporosis therapy--dawn of the post-bisphosphonate era.

Roland Baron1.   

Abstract

Over the past decade, investigators have actively searched for safer therapeutic approaches to replace or complement the use of bisphosphonates and/or parathyroid hormone, exploring both antiresorptive and osteoanabolic pathways. Besides marked progress in basic research, the year 2011 has seen several compounds for the treatment of osteoporosis enter or progress within clinical trials.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22143180     DOI： 10.1038/nrendo.2011.207

Source DB:  PubMed          Journal:  Nat Rev Endocrinol        ISSN： 1759-5029            Impact factor:   43.330


  10 in total

1.  Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass.

Authors:  Henry G Bone; Michael A Bolognese; Chui Kin Yuen; David L Kendler; Paul D Miller; Yu-Ching Yang; Luanda Grazette; Javier San Martin; J Christopher Gallagher
Journal:  J Clin Endocrinol Metab       Date:  2011-02-02       Impact factor: 5.958

2.  Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody.

Authors:  Desmond Padhi; Graham Jang; Brian Stouch; Liang Fang; Edward Posvar
Journal:  J Bone Miner Res       Date:  2011-01       Impact factor: 6.741

3.  Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis.

Authors:  Felicia Cosman; Erik Fink Eriksen; Chris Recknor; Paul D Miller; Núria Guañabens; Christian Kasperk; Philemon Papanastasiou; Aimee Readie; Hanumantha Rao; Jürg A Gasser; Christina Bucci-Rechtweg; Steven Boonen
Journal:  J Bone Miner Res       Date:  2011-03       Impact factor: 6.741

4.  Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk.

Authors:  S Boonen; J D Adachi; Z Man; S R Cummings; K Lippuner; O Törring; J C Gallagher; J Farrerons; A Wang; N Franchimont; J San Martin; A Grauer; M McClung
Journal:  J Clin Endocrinol Metab       Date:  2011-03-16       Impact factor: 5.958

5.  Safety and efficacy of the cathepsin K inhibitor ONO-5334 in postmenopausal osteoporosis: the OCEAN study.

Authors:  Richard Eastell; Shinichi Nagase; Michiyo Ohyama; Maria Small; James Sawyer; Steven Boonen; Tim Spector; Tomohiro Kuwayama; Steve Deacon
Journal:  J Bone Miner Res       Date:  2011-06       Impact factor: 6.741

6.  Effects of denosumab on bone turnover markers in postmenopausal osteoporosis.

Authors:  Richard Eastell; Claus Christiansen; Andreas Grauer; Stepan Kutilek; Cesar Libanati; Michael R McClung; Ian R Reid; Heinrich Resch; Ethel Siris; Daniel Uebelhart; Andrea Wang; Georges Weryha; Steve R Cummings
Journal:  J Bone Miner Res       Date:  2011-03       Impact factor: 6.741

7.  Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST).

Authors:  W Balemans; M Ebeling; N Patel; E Van Hul; P Olson; M Dioszegi; C Lacza; W Wuyts; J Van Den Ende; P Willems; A F Paes-Alves; S Hill; M Bueno; F J Ramos; P Tacconi; F G Dikkers; C Stratakis; K Lindpaintner; B Vickery; D Foernzler; W Van Hul
Journal:  Hum Mol Genet       Date:  2001-03-01       Impact factor: 6.150

8.  Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease.

Authors:  W Balemans; N Patel; M Ebeling; E Van Hul; W Wuyts; C Lacza; M Dioszegi; F G Dikkers; P Hildering; P J Willems; J B G M Verheij; K Lindpaintner; B Vickery; D Foernzler; W Van Hul
Journal:  J Med Genet       Date:  2002-02       Impact factor: 6.318

9.  Odanacatib in the treatment of postmenopausal women with low bone mineral density: three-year continued therapy and resolution of effect.

Authors:  John A Eisman; Henry G Bone; David J Hosking; Michael R McClung; Ian R Reid; Rene Rizzoli; Heinrich Resch; Nadia Verbruggen; Carolyn M Hustad; Carolyn DaSilva; Romana Petrovic; Arthur C Santora; B Avery Ince; Antonio Lombardi
Journal:  J Bone Miner Res       Date:  2011-02       Impact factor: 6.741

10.  Denosumab for prevention of fractures in postmenopausal women with osteoporosis.

Authors:  Steven R Cummings; Javier San Martin; Michael R McClung; Ethel S Siris; Richard Eastell; Ian R Reid; Pierre Delmas; Holly B Zoog; Matt Austin; Andrea Wang; Stepan Kutilek; Silvano Adami; Jose Zanchetta; Cesar Libanati; Suresh Siddhanti; Claus Christiansen
Journal:  N Engl J Med       Date:  2009-08-11       Impact factor: 91.245
  10 in total
  7 in total

1.  Effects of novel cathepsin K inhibitor ONO-5334 on bone resorption markers: a study of four sustained release formulations with different pharmacokinetic patterns.

Authors:  Makoto Tanaka; Yoshitaka Hashimoto; Noboru Sekiya; Naoki Honda; Steve Deacon; Masanobu Yamamoto
Journal:  J Bone Miner Metab       Date:  2013-10-11       Impact factor: 2.626

2.  YC-1 alleviates bone loss in ovariectomized rats by inhibiting bone resorption and inducing extrinsic apoptosis in osteoclasts.

Authors:  Jin-Wen Wang; Chin-Bin Yeh; Shao-Jiun Chou; Kuo-Cheng Lu; Tzu-Hui Chu; Wei-Yu Chen; Jui-Lin Chien; Mao-Hsiung Yen; Tien-Hua Chen; Jia-Fwu Shyu
Journal:  J Bone Miner Metab       Date:  2017-10-05       Impact factor: 2.626

3.  Ablation of Tak1 in osteoclast progenitor leads to defects in skeletal growth and bone remodeling in mice.

Authors:  Bing Qi; Qian Cong; Ping Li; Gang Ma; Xizhi Guo; James Yeh; Min Xie; Michael D Schneider; Huijuan Liu; Baojie Li
Journal:  Sci Rep       Date:  2014-11-24       Impact factor: 4.379

4.  Wedelolactone enhances osteoblastogenesis by regulating Wnt/β-catenin signaling pathway but suppresses osteoclastogenesis by NF-κB/c-fos/NFATc1 pathway.

Authors:  Yan-Qiu Liu; Zhi-Lai Hong; Li-Bin Zhan; Hui-Ying Chu; Xiao-Zhe Zhang; Guo-Hui Li
Journal:  Sci Rep       Date:  2016-08-25       Impact factor: 4.379

5.  Inhibition of cathepsin K promotes osseointegration of titanium implants in ovariectomised rats.

Authors:  Chun Yi; Ke-Yi Hao; Ting Ma; Ye Lin; Xi-Yuan Ge; Yu Zhang
Journal:  Sci Rep       Date:  2017-03-17       Impact factor: 4.379

6.  Synthesis and anti-osteoporosis activity of novel Teriparatide glycosylation derivatives.

Authors:  Nan Wang; Jingyang Li; Hui Song; Chao Liu; Honggang Hu; Hongli Liao; Wei Cong
Journal:  RSC Adv       Date:  2020-07-07       Impact factor: 4.036

7.  Differentiation of deer tendons from cattle tendons by a loop-mediated isothermal amplification (LAMP) test and bone remodeling bioassays.

Authors:  Li-Li Jiang; Cheuk-Lun Liu; Yuk-Lau Wong; Chun-Fong Nip; Pang-Chui Shaw
Journal:  Chin Med       Date:  2015-11-12       Impact factor: 5.455
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.